H1-3

Histone H1.3 · P16402 · H1-3 on Sugi Atlas →

0 patent compounds predicted against H1-3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to H1-3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia PHASE4COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) PHASE3COMPLETED
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) PHASE1/PHASE2NOT_YET_RECRUITING
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG PHASE1/PHASE2RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Vorinostat in Children PHASE1/PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer PHASE1/PHASE2COMPLETED
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1COMPLETED
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Intravenously Administered M6229 in Critically Ill Sepsis Patients PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma PHASE1ACTIVE_NOT_RECRUITING
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease PHASE1NOT_YET_RECRUITING
Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian PHASE1ACTIVE_NOT_RECRUITING
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1COMPLETED
Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Impact of Air Quality on the Effectiveness of Standard of Care Therapy in Children With Autism Spectrum Disorder: A Prospective Longitudinal Study nanNOT_YET_RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a H1-3 binder may also engage these)

ProteinNameSimilarity
P15867 1.000 P15867 →
P06893 1.000 P06893 →
P02253 1.000 P02253 →
P15866 1.000 P15866 →
Q02539 1.000 Q02539 →
H1-4 Histone H1.4 1.000 landscape →
P43277 1.000 P43277 →
P02251 1.000 P02251 →
H1-2 Histone H1.2 1.000 landscape →
P08287 1.000 P08287 →
P15864 1.000 P15864 →
P15865 1.000 P15865 →
P02252 1.000 P02252 →
P08288 1.000 P08288 →
A7MAZ5 1.000 A7MAZ5 →
P22844 0.999 P22844 →
Q5NVN9 0.998 Q5NVN9 →
P43275 0.997 P43275 →
P09426 0.997 P09426 →
P23444 0.997 P23444 →
H1-0 Histone H1.0 0.996 landscape →
P43274 0.996 P43274 →
P43276 0.996 P43276 →
G3N131 0.996 G3N131 →
D4A3K5 0.996 D4A3K5 →
Q9M5W4 0.995 Q9M5W4 →
D3ZBN0 0.995 D3ZBN0 →
P10922 0.994 P10922 →
P09987 0.994 P09987 →
P08285 0.994 P08285 →